Acorda Therapeutics discontinues development program for Parkinson's Disease treatment
The decision includes immediately discontinuing dosing of all participants currently enrolled in its tozadenant studies and is based on new information obtained from the Phase III program related to previously disclosed agranulocytosis and associated serious adverse events. After analyzing this additional information, the Company concluded that it could not be confident that weekly white blood cell count screening would sufficiently ensure patient safety.
Acorda has informed regulatory authorities and trial investigators regarding the orderly closure of ongoing studies.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.